# EDGAR Filing Document

**Accession Number:** 0001739104
**File Stem:** 0001104659-26-067002
**Filing Date:** 2026-5
**Character Count:** 6050
**Document Hash:** 2a9d8aba72711eb0942ca4b84583ea8b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-067002.hdr.sgml**: 20260527

**ACCESSION NUMBER**: 0001104659-26-067002

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260521

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260527

**DATE AS OF CHANGE**: 20260527

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Elanco Animal Health Inc
- **CENTRAL INDEX KEY:** 0001739104
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825497352
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38661
- **FILM NUMBER:** 261027311

**BUSINESS ADDRESS:**
- **STREET 1:** 450 ELANCO CIRCLE
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46221
- **BUSINESS PHONE:** 877-352-6261

**MAIL ADDRESS:**
- **STREET 1:** 450 ELANCO CIRCLE
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46221

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington** **, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **May 21, 2026**

**Elanco Animal Health Incorporated**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Indiana** | **001-38661** | **82-5497352** |
| (State or other jurisdiction <br> of incorporation) | (Commission <br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **450 Elanco Circle**<br> **Indianapolis** **, Indiana**<br> (Address of principal executive offices) | **46221**<br> (Zip Code) |

---

Registrant's telephone number, including area code: **(877) 352-6261**

**Not Applicable**

(Former Name or Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | &nbsp;&nbsp;**Trading Symbol(s)** | &nbsp;&nbsp;**Name of each exchange on which<br> registered** |
| Common stock, no par value | &nbsp;&nbsp;ELAN | &nbsp;&nbsp;New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

◻ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

Elanco Animal Health Incorporated (the "Company") held its annual meeting of shareholders on May 21, 2026. Voting results for each matter submitted to a vote at the 2026 annual meeting are provided below.

**Proposal 1.** Election of Directors. All of the nominees nominated by the Board for director were elected to serve for a one-year term ending at the 2027 annual meeting of shareholders and until their respective successors are elected and qualified, by the votes set forth in the table below.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Class I Nominees** | **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
| Kapila K. Anand |  | 375459071 |  | 91840502 |  | 655918 |  | 15365167 |
| Paul Herendeen |  | 441252058 |  | 26575629 |  | 127804 |  | 15365167 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Class II Nominees** | **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
| Michael Harrington |  | 373406333 |  | 94421261 |  | 127897 |  | 15365167 |
| Lawrence Kurzius |  | 442964897 |  | 24863542 |  | 127052 |  | 15365167 |
| Kirk McDonald |  | 440842458 |  | 26978663 |  | 134370 |  | 15365167 |

---

**Proposal 2.** The shareholders ratified the appointment of Ernst & Young LLP as Elanco's independent registered public accounting firm for 2026, by the votes set forth in the table below.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For** | **Against** | **Against** | **Abstain** | **Abstain** |
| 480470647 |  | 2611450 |  | 238561 |

---

**Proposal 3.** The shareholders approved, by non-binding vote, the compensation of Elanco's named executive officers, by the votes set forth in the table below.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
| 383528222 |  | 84173798 |  | 253471 |  | 15365167 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Elanco Animal Health Incorporated | Elanco Animal Health Incorporated |
| Date: May 27, 2026 | *By:* | /s/ Shiv O'Neill |
|  |  | *Name:* Shiv O'Neill |
|  |  | *Title:* Executive Vice President, General Counsel and Corporate Secretary |

---